Senores Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Senores Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-5 of operating cash. Lower than 94% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-5Over the last 3 years, every ₹100 of reported profit came with ₹-5 of operating cash.
Lower than 94% of Healthcare companies in India.
Self-Funding Ratio
-0.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Healthcare companies in India.
Cash Locked Ratio
₹21For every ₹100 of sales, ₹21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹19 tied up three years earlier.
Less money tied up than 57% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹18Sales grew 1,639% in 3 years; of every extra ₹100 of sales, ₹18 became extra profit.
Higher than 53% of Healthcare companies in India.
Asset Productivity Ratio
+1639% / +1124%In 3 years sales changed by +1639% while total assets changed by +1124%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.5×Debt due within a year is covered 0.5 times by its yearly operating cash.
Lower than 72% of Healthcare companies in India.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 57% of Healthcare companies in India.
Tangible Assets Ratio
76%Of every ₹100 the company owns, ₹76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 87% of Healthcare companies in India.
Tangible Net Worth Ratio
59%Of every ₹100 of net worth, ₹59 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 86% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Senores Pharmaceuticals Limited owes ₹0.40 for every ₹1 it owns. Net profit rose 97% in the year to Mar 2026, and grew 139% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
42.4Investors pay ₹42.4 for every ₹1 of Senores Pharmaceuticals Limited's yearly profit, higher than 59% of Healthcare companies in India.
P/B ratio
5.93The share price is 5.93 times Senores Pharmaceuticals Limited's book value per share, higher than 65% of Healthcare companies in India.
Market cap
₹5,538 CrThe total market value of all of Senores Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹934 CrWhat Senores Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹202.72Net worth divided by the number of shares. The share price of ₹1,203 is 5.9 times this, which is the P/B above.
Return on equity (ROE)
12.1%Senores Pharmaceuticals Limited earned 12.1% on its shareholders' money over the last year, lower than 54% of Healthcare companies in India.
Owes vs Owns
0.40×Senores Pharmaceuticals Limited owes ₹0.40 for every ₹1 it owns (low), higher than 59% of Healthcare companies in India.
Dividend yield
NoneSenores Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
+61%Revenue rose 61% in the year to Mar 2026, and grew 159% a year on average over 3 years.
Profit growth
+97%Net profit rose 97% in the year to Mar 2026, and grew 139% a year on average over 3 years.
Profit margin
18.8%Senores Pharmaceuticals Limited keeps ₹19 of every ₹100 of revenue as net profit.
Cash quality
0.5×Cash from Senores Pharmaceuticals Limited's business was 0.5× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
5.9×Senores Pharmaceuticals Limited's operating profit covered its interest costs 5.9 times in the year to Mar 2026.
Cash vs debt
Net debtSenores Pharmaceuticals Limited had ₹182 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Senores Pharmaceuticals Limited's P/E ratio?
Investors pay ₹42.4 for every ₹1 of Senores Pharmaceuticals Limited's yearly profit, higher than 59% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Senores Pharmaceuticals Limited: ₹5,538 Cr ÷ ₹934 Cr (31 Mar 2026) = 5.9.
What is Senores Pharmaceuticals Limited's return on equity?
Senores Pharmaceuticals Limited earned 12.1% on its shareholders' money over the last year, lower than 54% of Healthcare companies in India.
How much does Senores Pharmaceuticals Limited owe compared with what it owns?
Senores Pharmaceuticals Limited owes ₹0.40 for every ₹1 it owns (low), higher than 59% of Healthcare companies in India.
Does Senores Pharmaceuticals Limited pay a dividend?
No. Senores Pharmaceuticals Limited does not currently pay a dividend.
Is Senores Pharmaceuticals Limited's revenue growing?
Revenue rose 61% in the year to Mar 2026, and grew 159% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.